Page 56 - Read Online

Biersack. Cancer Drug Resist 2019;2:1-17 I http://dx.doi.org/10.20517/cdr.2019.09 Page 15

51. Al-Khanbashi M, Caramuta S, Alajmi AM, Al-Haddabi I, Al-Riyami M, et al. Tissue and serum miRNA profile in locally advanced
breast cancer (LABC) in response to neo-adjuvant chemotherapy (NAC) treatment. PLoS One 2016;11:e152032.
52. Hu Y, Qiu Y, Yagüe E, Ji W, Liu J, et al. MiRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast
cancer. Cell Death Dis 2016;7:e2291.
53. Hu H, Li S, Cui X, Lv X, Jiao Y, et al. The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human
breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem 2013;288:10973-85.
54. Kolacinska A, Morawiec J, Fendler W, Malachowska B, Morawiec Z, et al. Association of microRNAs and pathogenic response to
preoperative chemotherapy in triple negative breast cancer: preliminary report. Mol Biol Rep 2014;41:2851-7.
55. García-Vazquez R, Ruiz-Garzía E, García AM, Astudillo-de la Vega H, Lara-Medina F, et al. A microRNA signature associated
with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumor Biol
2017;39:1010428317702899.
56. Hubaux R, Vandermeers F, Cosse JP, Crisanti C, Kapoor V, et al. Valproic acid improves second-line regimen of small cell lung
carcinoma in preclinical models. ERJ Open Res 2015;1:00028-2015.
57. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 2009;37:2112-7.
58. Ravery V, Fizazi K, Oudard S, Drouet L, Eymard JC, et al. The use of estramustine phosphate in the modern management of advanced
prostate cancer. BJU Int 2011;108:1782-6.
59. Wei C, Pan Y, Huang H, Li YP. Estramustine phosphate induces prostate cancer cell line PC3 apoptosis by down-regulating miR-31
levels. Eur Rev Med Pharmacol Sci 2018;22:40-5.
60. Lin X, Wang Y. Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression. Clin Transl Oncol
2018;20:1400-7.
61. Teimouri F, Nikfar S, Abdollahi M. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of
malignant melanoma: a meta-analysis consisting of 1314 patients. Melanoma Res 2013;23:381-9.
62. Zhu W, Zhou L, Qian JQ, Qiu TZ, Shu YQ, et al. Temozolomide for the treatment of brain metastases: a review of 21 clinical trials.
World J Clin Oncol 2014;5:19-27.
63. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-
clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
64. Chen YN. Dacarbazine inhibits proliferation of melanoma FEMX-1 cells by up-regulating expression of miRNA-200. Eur Rev Med
Pharmacol Sci 2017;21:1191-7.
65. Jones K, Nourse JP, Keane C, Bhatnagar A, Gandhi MK. Plasma microRNA are disease response biomarkers in classical Hodgkin
lymphoma. Clin Cancer Res 2013;20:253-64.
66. Shi L, Chen J, Yang J, Pan T, Zhang S, et al. MiR-21 protected human glioblastoma U78MG cells from chemotherapeutic drug
temozolomide induced apoptosis be decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010;1352:255-64.
67. Zhang S, Wan Y, Pan T, Gu X, Qian C, et al. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to
chemotherapeutic drug temozolomide. J Mol Neurosci 2012;47:346-56.
68. Wong ST, Zhang XQ, Zhuang JT, Chan HL, Li CH, et al. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-
resistant glioblastoma cells. Anticancer Res 2012;32:2835-41.
69. Gwak HS, Kim TH, Jo GH, Kim YJ, Kwak HJ, et al. Silencing of microRNA-21 confers radio-sensitivity through inhibition of the
PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS One 2012;7:e47449.
70. Comincini S, Allavena G, Palumbo S, Morini M, Durando F, et al. MicroRNA-17 regulates the expression of ATG7 and modulates the
autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells.
Cancer Biol Ther 2013;14:574-86.
71. Ananta JS, Paulmurugan R, Massoud TF. Nanoparticle-delivered antisense microRNA-21 enhances the effects of temozolomide on
glioblastoma. Mol Pharmaceutics 2015;12:4509-17.
72. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, et al. MiR-195, miR-455-3p and miR-10a(*) are implicated in acquired
temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 2010;296:241-8.
73. Tezcan G, Tunca B, Bekar A, Preusser M, Berghoff AS, et al. MicroRNA expression pattern modulates temozolomide response in GBM
tumors with cancer stem cells. Cell Mol Neurobiol 2014;34:679-92.
74. Cirilo PDR, de Sousa Andrade LN, Corrêa BRS, Qiao M, Furuya TK, et al. MicroRNA-195 acts as an anti-proliferative miRNA in
human melanoma cells by targeting prohibitin 1. BMC Cancer 2017;17:750.
75. Munoz JL, Rodriguez-Cruz V, Rameshwar P. High expression of miR-9 in CD133(+) glioblastoma cells in chemoresistance to
temozolomide. J Cancer Stem Cell Res 2015;3:e1003.
76. Munoz JL, Rodriguez-Cruz V, Ramkissoon SH, Ligon KL, Greco SJ, et al. Temozolomide resistance in glioblastoma occurs by miRNA-
9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget 2015;6:1190-201.
77. Stojcheva N, Schechtmann G, Sass S, Roth P, Florea AM, et al. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma
by targeting the Bcl-2-interacting mediator BIM. Oncotarget 2016;7:12937-50.
78. Han J, Chen Q. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells. Int J Clin Exp Pathol
2015;8:12698-707.
79. Luo H, Chen Z, Wang S, Zhang R, Qiu W, et al. C-Myc-miR-29c-REV3L signaling pathway drives the acquisition of temozolomide
resistance in glioblastoma. Brain 2015;138:3654-72.
80. Xiao S, Yang X, Qiu X, Lv R, Liu J, et al. MiR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylgunine-